Additional analyses of the weight-lowering efficacy of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomized trial
F Greenway, C le Roux, D Lau, A Astrup, K Fujioka, A Halpern, M Krempf, RV Ortiz, J Wilding, CB Svendsen, CB Jensen, X Pi-Sunyer, J Kienhöfer, A Segner · Diabetologie und Stoffwechsel · 2015 · Heft 08
Bibliografische Angaben
Zusammenfassung
Background: Safety and efficacy of liraglutide 3.0 mg, adjunct to 500 kcal/day dietary deficit and exercise, for weight management, was investigated. Methods: Adults (BMI ≥27 kg/m2 with ≥1 comorbidity or ≥30 kg/m2) were randomized 2:1 to once-daily s.c. liraglutide 3.0 mg (n = 2487) or placebo (n = 1244). Data are observed means for the full analysis set (exposed individuals with ≥1 post-baseline assessment) with LOCF at week 56, unless stated otherwise. Statistical analyses are estimated treatment differences (ETD; ANCOVA, continuous variables) or odds ratios (OR; logistic regression, categorical). Baseline BMI…
